\- Patients with histologically verified breast cancer and neoadjuvant or adjuvant treatment with a taxane derivate (e.g., Paclitaxel, Docetaxel): This group was chosen due to relatively high risk of neuropathy due to this special therapeutic agent 1,9.
Cumulative dose of at least 3 cycles
Interval of 2 weeks since the last chemotherapeutic cycle in order to prevent false worsenings due to delayed neurotoxic effects
Life expectancy of at least 3 months
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2 (that is, the capability to walk and to spend less than 50% of waking hours sitting or lying)
Ability to walk (with or without aids)
European Organisation for Research and Treatment of Cancer (EORTC) common toxicity criteria (CTC) peripheral sensory neuropathy grade 1 or 2
Intensity of paresthesias of \> 3/10 on the Visual Analog Scale (VAS)
You may not be if
\- Prevalent neuropathy of different etiology
Serious central-neurological or psychiatric disorder that would interfer with a proper order of the study, according to the judgement of the investigators
Epilepsy
Minors or persons unable to give informed consent
Current neurotoxic medication
Implanted pacemakers or defibrillators
Pregnancy
Wounds in the area to be treated, acute local or systemic infection
